This podcast focuses on applications of Real World Evidence including FDA criteria for accepting RWE, types of data, RWE study designs and the Totality of Evidence approach.
There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for applications including regulatory decisions, health technology assessment (HTA), pharmacovigilance and more. However, Asia currently lacks a framework to effectively collect and utilize a broad range of RWD/RWE.
This MAPS podcast details potential areas for compliant collaboration by MSLs with Patient Advocacy Groups.
This webinar explores WHAT is IIR vs. Collaborative Research and discusses the challenges of conducting IIR and Collaborative Research.
When quantitative and qualitative Field Medical KPIs and metrics are aligned with the organization’s strategic plan, these measurements demonstrate value. Defining and communicating this value is an essential task as Field Medical solidifies its role as a strategic pillar within the organization.
This paper discusses the sources and uses of non-registrational evidence and describes why Medical Affairs is positioned to lead and own the nRE Strategic Plan.
This session provides a learning opportunity for our audience by providing background on FDA’s Offices of Minority Health and Health Equity, and Women’s Health
MedInfo Teams contribute to the business with clinical expertise, extensive knowledge of the company products and medical literature, insights of customer needs, and a strong understanding of the business.
The objective of this podcast is to discuss how the 21st Century Cures Act has led to new initiatives at FDA involving Real World Evidence.
MAPS speaks with co-leads of the Insights Focus Area Working Group (FAWG) about the current state and future directions for Insights in Medical Affairs.